Resources Repository
-
ArticlePublication 2015Universal Public Finance of Tuberculosis Treatment in India: An Extended CEA
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India …
This paper evaluates the consequences of universal public finance (UPF) for tuberculosis treatment in India using extended cost-effectiveness analysis (ECEA). The authors evaluated the impact of UPF on health gains, financial consequences, and catastrophic health expenditures, and concluded that the health gains and insurance value of UPF would accrue mostly to the poor. However, reductions in out-of-pocket expenditures were found to be more uniformly distributed across income quintiles. A variant on the base case suggests…
Cost-Effectiveness Analysis | Economics/Finance | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Social Determinants | Health Systems | Policy/Regulation | Clinical Care | Health/Medicine | Asia & Pacific -
ArticlePublication 2015Extended CEA: Surgical Access in Ethiopia
This chapter presents an extended cost-effectiveness analysis of strategies to improve access to surgical care …
This chapter presents an extended cost-effectiveness analysis of strategies to improve access to surgical care in rural Ethiopia, providing information on the health and financial risk protection benefits of policies. This chapter is from Essential Surgery, the first volume in the Disease Control Priorities, third edition (DCP3) series. The volume presents data on the surgical burden of disease, disability, congenital anomalies, and trauma, along with health impact and economic analyses of procedures, platforms, and packages…
Cost-Effectiveness Analysis | Economics/Finance | Child/Nutrition | Priority Setting/Ethics | Costing Methods | Maternal/Reproductive Health | Health Systems | Health/Medicine | Sub-Saharan Africa -
ReviewPublication 2013Role of Health Economic Analyses in Vaccine Decision Making
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in …
Beginning in the 20th century with the consideration of the seven-valent pneumococcal conjugate vaccine in the US, cost effectiveness became a topic of discussion when a vaccine was being considered for universal use by the US Advisory Committee on Immunization practices (ACIP). In 2008, the ACIP began using formal criteria for the presentation of such data and their inclusion in ACIP discussions. More recently, the U.S. Institute of Medicine has recommended that health economic considerations play a…
Cost-Effectiveness Analysis | Economics/Finance | Infectious Diseases | Priority Setting/Ethics | Health Systems | Health/Medicine | North America -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Cost-Effectiveness Analysis | Economics/Finance | Infectious Diseases | Costing Methods | Health Outcomes | Chronic Disease/Risk | Health Systems | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific